CTOs on the Move

Versicolor Technologies

www.versicolortechnologies.com

 
Versicolor Technologies has developed the world`s first cosmetic and therapeutic technology platform to address pigmentation and skin aging, by leveraging small molecule compounds produced naturally in the human microbiome.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Invacare Supply Group

Invacare Supply Group is a Milford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gaiam, Inc.

Gaiam, Inc. (Gaiam) is a lifestyle media company providing a selection of information, media, products and services to customers, who value personal development, wellness, ecological lifestyles, responsible media and conscious community.

Moore Medical Corp.

Moore Medical Corp. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Farmington, CT. To find more information about Moore Medical Corp., please visit www.mooremedical.com

OKC-County Health Department

The OKC-County Health Department serves the residents of Oklahoma County by promoting and protecting health, preventing disease, and creating partnerships.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.